EMA Authorised: Onivyde pegylated liposomal (previously Onivyde) (irinotecan anhydrous free-base) — Les Laboratoires Servier

View source ↗

Summary

The European Medicines Agency authorised a pegylated liposomal form of irinotecan (Onivyde) for pancreatic neoplasms, with Les Laboratoires Servier as the marke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Onivyde pegylated liposomal irinotecan (irinotecan anhydrous free-base)

Snippet

Status: Authorised. Therapeutic area: Pancreatic Neoplasms. MAH: Les Laboratoires Servier. Decision date: 28/11/2024. Orphan medicine